## Edgar Filing: TEVA PHARMACEUTICAL INDUSTRIES LTD - Form SD

TEVA PHARMACEUTICAL INDUSTRIES LTD Form SD May 31, 2017

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM SD SPECIALIZED DISCLOSURE REPORT

TEVA PHARMACEUTICAL INDUSTRIES LIMITED (Exact name of the registrant as specified in its charter)

ISRAEL001-16174(State or other jurisdiction(Commission (IRS Employerof incorporation or organization)File Number)Identification No.)

5 Basel Street, Petach Tikva, Israel 4951033
(Address of principal executive offices) (Zip code)
Eyal Desheh
Group Executive Vice President, Chief Financial Officer
Tel: 972-3-914-8171
(Name and telephone number, including area code, of the person to contact in connection with this report.)

Check the appropriate box to indicate the rule pursuant to which this form is being filed and provide the period to which the information in this form applies:

Rule 13p-1 under the Securities Exchange Act (17 CFR 240.13p-1) for the reporting period from January 1 to December 31, 2016.

Items 1.01 and 1.02 Conflict Minerals Disclosure, Exhibit

Conflict Minerals Disclosure and Report

A copy of the Company's Conflict Minerals Report is provided as Exhibit 1.02 hereto and is publicly available at

http://www.tevapharm.com/files/about/corporate governance/governance doc/Teva Conflict Minerals Policy Statement.pdf Item 2.01 Exhibits

Listed below is the following exhibit filed as part of this report:

Exhibit 1.01 – Conflict Minerals Report as required by Item 1.01 and 1.02 of this Form.

## Edgar Filing: TEVA PHARMACEUTICAL INDUSTRIES LTD - Form SD

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the duly authorized undersigned.

TEVA PHARMACEUTICAL INDUSTRIES LIMITED (Registrant)

/s/ Eyal Desheh

By Eyal Desheh Group Executive Vice President, Chief Financial Officer May 31, 2017